Riding the pepTIDE — The Daily Wire on Therapeutic Peptides

An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.

Topic Sections

  • Top Shots — The most significant peptide and longevity stories ranked by overall editorial score
  • Research Signals — High-credibility scientific findings from journals, preprints, and clinical sources
  • Healing & Recovery — Tissue repair, injury recovery, and gut healing peptides including BPC-157 and TB-500
  • Growth Hormone Wire — Growth hormone secretagogues, peptide stacks, and GH axis research including Ipamorelin, CJC-1295, and MK-677
  • Metabolic & GLP-1 — Metabolic health, insulin sensitivity, and GLP-1 receptor agonist research including semaglutide and tirzepatide
  • Cognitive / Nootropic — Peptides targeting brain function, memory, neuroprotection, and cognitive enhancement
  • Skin & Cosmetic — Skin repair, anti-aging, collagen synthesis, and cosmetic peptide research including GHK-Cu and matrixyl
  • Reddit Finds — Community-sourced discussions, self-experimentation reports, and protocol threads from peptide communities
  • Contrarian Takes — Alternative viewpoints, dissenting research, and perspectives that challenge mainstream peptide narratives
  • Skeptic's Corner — Hype debunking, low-evidence alerts, and critical analysis of overstated peptide claims

Browse by Filter

  • Newest — Latest peptide and longevity stories
  • Most Credible — Highest credibility-scored stories
  • Most Edgy — High-novelty, unconventional findings
  • Most Discussed — Trending community discussions
  • Most Actionable — Direct applicability to daily health protocols
  • Lowest Risk — Stories with strong evidence, low hype
  • Research Only — Peer-reviewed and preprint studies
  • Reddit Only — Community discussion and anecdote
  • GLP-1 / Metabolic — Semaglutide, tirzepatide, and metabolic peptides
  • Healing / Recovery — BPC-157, TB-500, and repair protocols

More

  • About Riding the pepTIDE
  • Health Disclaimer
  • Submit a Source
  • Contact

Thinking of Mounjaro to lose 15 kg? Users weigh in on risks

Someone online asked whether using Mounjaro to lose about 15 kg (33 lb) makes sense for them. They’re 37, 1.66 m tall, currently 78 kg, and were recently diagnosed with fatty liver disease. They’re curious because they’ve heard these drugs can be life-changing for people who need to lose a lot of weight, and want to know if it’s a sensible option for a more moderate goal. Mounjaro is the brand name for tirzepatide. It’s a prescription medicine injected under the skin that acts on hormone receptors involved in appetite and blood sugar. In plain terms, it tricks parts of your body—mainly in the gut and brain—into reducing hunger and slowing how quickly food leaves the stomach, so you feel fuller longer. It was developed to treat type 2 diabetes but also lowers weight as a side effect, and doctors now sometimes prescribe it primarily for weight loss. What research shows: large clinical trials tested tirzepatide in hundreds to thousands of people. On average, people lost substantially more weight than with older drugs—often double-digit percentages of body weight over months. But results vary a lot. Trials usually include people with obesity or overweight plus health issues like diabetes. There’s less definitive data for someone whose target is a moderate 15 kg drop from a lower starting weight. Also, trial conditions include medical oversight, dosing schedules, and lifestyle support; real-world results can differ. Why it matters: if you have fatty liver disease (nonalcoholic fatty liver disease), even modest weight loss can improve liver health. A 5–10% body weight reduction often reduces liver fat and inflammation. For someone at 78 kg, losing 15 kg is more than that threshold and could help. Mounjaro could be a useful tool if diet and exercise alone haven’t worked, especially when liver disease or metabolic risk is present. It’s particularly relevant when weight loss would improve health rather than only cosmetic goals. Caveats and risks: tirzepatide needs a prescription and medical follow-up. Common side effects include nausea, diarrhea, vomiting and constipation; these are often worse at first and can be managed by slow dose increases. There are rare but serious risks that clinicians watch for, like pancreatitis (pancreas inflammation) and gallbladder problems. We don’t have long-term safety data spanning many years for every use-case. Stopping the drug can lead to weight regain unless lifestyle changes are maintained. It’s not appropriate for people with certain medical histories (for example, a personal or family history of certain rare thyroid cancers) and it’s not a one-size-fits-all solution. Bottom line: tirzepatide (Mounjaro) can produce big weight loss and might help with fatty liver, but it should be considered with a doctor who can weigh benefits, side effects, and long-term plans. If your goal is a 15 kg loss, discuss medical eligibility, realistic expectations, and a plan to keep the weight off after stopping the medication.

Source: r/Mounjaro

Read full story

Back to Riding the pepTIDE